In conclusion, targeted deletion of PRDX1 enhances anti‐tumor immunity in CRC by reprogramming the immunosuppressive TAMs, revealing a novel role of PRDX1 as a potential drug target during anti‐tumor immunotherapy. This evidence concerns the gene PRDX1 and neoplasm.